Answers are grounded in this paper and cite their sources.
Low-grade serous ovarian cancer (LGSOC) is a rare malignancy with limited responsiveness to chemotherapy, highlighting the urgent need for novel therapeutic strategies to improve treatment outcomes. Immune checkpoint inhibitors, such as pembrolizumab, have demonstrated efficacy in various cancers, including certain ovarian cancer subtypes, and could represent a promising treatment option for LGSOC.
No takes yet. Share an insight, caveat, or question.
Grabowski et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: